Age, median (range), y
|
61 (20–83)
|
61.5 (24–79)
|
ECOG performance statusb
|
0
|
46 (35)
|
10 (31)
|
1
|
66 (51)
|
17 (53)
|
2
|
17 (13)
|
5 (16)
|
International Prognostic Index, n (%)
|
<2
|
31 (24)
|
7 (22)
|
≥2
|
99 (76)
|
25 (78)
|
PTCL subtype based on central review, n (%)
|
PTCL-NOS
|
69 (53)
|
16 (50)
|
AITL
|
27 (21)
|
8 (25)
|
ALK-1-negative ALCL
|
21 (16)
|
5 (16)
|
Other
|
13 (10)c
|
3 (9)d
|
Stage III/IV at diagnosis, n (%)
|
91 (70)
|
20 (63)
|
Number of prior therapies, n (%)
|
1
|
38 (29)
|
13 (41)
|
2
|
44 (34)
|
11 (34)
|
3
|
19 (15)
|
3 (9)
|
4
|
15 (12)
|
4 (13)
|
>4
|
14 (11)
|
1 (3)
|
Type of prior therapy, n (%)
|
Chemotherapy
|
129 (99)
|
31 (97)
|
Monoclonal antibody therapy
|
20 (15)
|
3 (9)
|
Other immunotherapy
|
14 (11)
|
1 (3)
|
Radiation
|
31 (24)
|
8 (25)
|
ASCT
|
21 (16)
|
3 (9)
|
Refractory to most recent therapy, n (%)
|
49 (38)
|
8 (25)
|